Please login to the form below

Not currently logged in
Email:
Password:

Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

Lung cancer treatment will be available to NHS patients while NICE awaits data
AstraZeneca's Tagrisso

AstraZeneca's Tagrisso (osimertinib) has become the first drug to be supported by the UK's newly-reformed Cancer Drugs Fund (CDF).

Now overseen by the National Institute for Health and Care Excellence (NICE), the CDF will make Tagrisso available to NHS England patients on a 'managed access' basis.

This will continue while NICE awaits further data on the first-in-class non-small cell lung cancer (NSCLC) treatment, which won European approval in February.

AstraZeneca UK and Ireland country president Lisa Anson said: “We are very proud that NHS patients in England now have access to osimertinib.

“This is a great example of partnership between clinicians, AstraZeneca, the Department of Health, NICE, NHS England and other stakeholders to ensure that UK patients gain access to an innovative medicine while further data are gathered.”

Cost-effectiveness watchdog NICE has yet to recommend Tagrisso for general NHS use, and is currently awaiting the results of ongoing studies into the NSCLC drug's long-term effectiveness.

In the meantime, the recently-relaunched CDF will give around 300 patients across England and Wales access to Tagrisso as a second-line treatment for advanced metastatic EGFR T790M mutation-positive NSCLC.

Professor Carole Lonson, director of NICE's health technology evaluation centre, said: “For the first time, we are able to give patients access to a promising new cancer treatment while more evidence is gathered on its effectiveness. This is the system working as it should.”

Tagrisso is designed to target both the EGFR mutation, which triggers cancer growth, and the T790M mutation, which creates resistance to existing NSCLC treatments, such as Roche and Astellas' Tarceva (erlotinib), AZ's Iressa (gefitinib) and Boehringer Ingelheim's Giotrif (afatinib).

In two AURA phase II trials, 66% of patients with both mutations saw their tumours shrink, with an average progression free survival of 11 months.

AZ's drug had previously been made available to UK patients through an early access scheme, funded entirely by the pharma company, between December 2015 and February 2016 ahead of EU marketing authorisation.

Article by
Rebecca Clifford

4th October 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

How Can We Make Payer Communications Really Sing?
With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
So how do you really engage with patients?
The most valuable insights from patient engagement are the most unexpected ones. Simple things, which may seem unimportant to you, may be the key to making patients’ lives easier and...

Infographics